These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25067937)

  • 1. Effects of the Chemokine Receptor 5 (CCR5)-Delta32 Mutation on Hepatitis C Virus-Specific Immune Responses and Liver Tissue Pathology in HCV Infected Patients.
    Yilmaz A; Alagozlu H; Ozdemir O; Arici S
    Hepat Mon; 2014 Jul; 14(7):e11283. PubMed ID: 25067937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.
    Ahlenstiel G; Woitas RP; Iwan A; Nattermann J; Feldmann G; Rockstroh JK; Oldenburg J; Kupfer B; Sauerbruch T; Spengler U
    Immunol Invest; 2009; 38(3-4):284-96. PubMed ID: 19811439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Schirin-Sokhan R; Gartung C; Lorenzen J; Matern S; Lammert F
    J Mol Med (Berl); 2004 Jan; 82(1):64-9. PubMed ID: 14673528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.
    Woitas RP; Ahlenstiel G; Iwan A; Rockstroh JK; Brackmann HH; Kupfer B; Matz B; Offergeld R; Sauerbruch T; Spengler U
    Gastroenterology; 2002 Jun; 122(7):1721-8. PubMed ID: 12055576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.
    Ahlenstiel G; Woitas RP; Iwan A; Nattermann J; Feldmann G; Rockstroh JK; Oldenburg J; Kupfer B; Sauerbruch T; Spengler U
    Immunol Invest; 2009; 38(1):1-13. PubMed ID: 19172482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.
    El-Moamly AA; El-Sweify MA; Rashad RM; Abdalla EM; Ragheb MM; Awad MM
    Parasitol Res; 2013 Jul; 112(7):2745-52. PubMed ID: 23515570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.
    Ahlenstiel G; Berg T; Woitas RP; Grünhage F; Iwan A; Hess L; Brackmann HH; Kupfer B; Schernick A; Sauerbruch T; Spengler U
    J Hepatol; 2003 Aug; 39(2):245-52. PubMed ID: 12873822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of the CCR5-Delta32 mutant allele is not increased in Belgian hepatitis C virus-infected patients.
    Thoelen I; Verbeeck J; Wollants E; Maes P; Robaeys G; Matheï C; Buntinx F; Nevens F; Van Ranst M
    Viral Immunol; 2005; 18(1):232-5. PubMed ID: 15802968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?
    Ahlenstiel G; Woitas RP; Rockstroh J; Spengler U
    J Antimicrob Chemother; 2004 Jun; 53(6):895-8. PubMed ID: 15128728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation.
    Nattermann J; Timm J; Nischalke HD; Olbrich A; Michalk M; Tillmann HL; Berg T; Wedemeyer H; Tenckhoff H; Wiese M; Kullig U; Göbel U; Capka E; Schiefke I; Güthof W; Grüngreiff K; König I; Roggendorf M; Sauerbruch T; Spengler U;
    J Hepatol; 2011 Dec; 55(6):1201-6. PubMed ID: 21703201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Study on the Association between
    Bineshian F; Hosseini A; Sharifi Z; Aghaie A
    Avicenna J Med Biotechnol; 2018; 10(4):261-264. PubMed ID: 30555661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between CCR5
    Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
    Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect of CCR5-Δ32 against HIV infection by the heterosexual mode of transmission in a Polish population.
    Zwolińska K; Knysz B; Rybka K; Pazgan-Simon M; Gąsiorowski J; Sobczyński M; Gładysz A; Piasecki E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):54-60. PubMed ID: 22957692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.
    Goulding C; McManus R; Murphy A; MacDonald G; Barrett S; Crowe J; Hegarty J; McKiernan S; Kelleher D
    Gut; 2005 Aug; 54(8):1157-61. PubMed ID: 15863470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of higher frequency of the chemokine receptor 5-delta32/delta32 genotype in hepatitis C.
    Tommasi AM; Fabris P; Carderi I; Baragiotta A; Baldo V; Venturi C; Giordani MT; Tositti G; Floreani A
    J Clin Gastroenterol; 2006; 40(5):440-3. PubMed ID: 16721228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5Δ32 in HCV infection, HCV/HIV co-infection, and HCV-related diseases.
    Ellwanger JH; Leal BK; Valverde-Villegas JM; Simon D; Marangon CG; Mattevi VS; Lazzaretti RK; Sprinz E; Kuhmmer R; Chies JAB
    Infect Genet Evol; 2018 Apr; 59():163-166. PubMed ID: 29408489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CCR5-Δ32 mutation among individuals with high risk behaviors, neonates born to HIV-1 infected mothers, HIV-1 infected individuals, and healthy people in an Iranian population.
    Donyavi T; Bokharaei-Salim F; Nahand JS; Garshasbi S; Esghaei M; Sadeghi M; Jamshidi S; Khanaliha K
    J Med Virol; 2020 Aug; 92(8):1158-1164. PubMed ID: 31854469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
    Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
    Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCR5 Polymorphism as a Protective Factor for Hepatocellular Carcinoma in Hepatitis B Virus-Infected Iranian Patients.
    Abdolmohammadi R; Shahbazi Azar S; Khosravi A; Shahbazi M
    Asian Pac J Cancer Prev; 2016 Oct; 17(10):4643-4646. PubMed ID: 27892677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.
    Hütter G; Neumann M; Nowak D; Klein S; Klüter H; Hofmann WK
    J Inflamm (Lond); 2011 Oct; 8():29. PubMed ID: 22029606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.